natgillin/translations-raw huggingface dataset:
To store fase III-studier blev designet for at undersøge behandlingseffekten af Avastin i kombination med to individuelle kemoterapeutika, målt ved det primære endepunkt progressionsfri overlevelse (PFS). 
Two large Phase III trials were designed to investigate the treatment effect of Avastin in combination with two individual chemotherapy agents, as measured by the primary endpoint of PFS. A clinically meaningful and statistically significant improvement in PFS was observed in both trials.
I kliniske studier omhandlende lokalt recidiverende eller metastatisk brystkræft blev der observeret sårhelingskomplikationer af grad 3-5 hos op til 1,1 % af patienterne, som fik Avastin, og hos op til 0,9 % af patienterne i kontrolarmene (NCI-CTCAE v. 3). 
In locally recurrent and metastatic breast cancer trials, Grade 3-5 wound healing complications were observed in up to 1.1% of patients receiving Avastin compared with up to 0.9% of patients in the control arms (NCI-CTCAE v.3).
• inflammation (betændelseslignende reaktion) i slimhinder i mund og tarme, lunger og luftveje, 
• inflammation of the moist lining of mouth and gut, lungs and air passages, reproductive, and urinary tracts,
(p-værdi = 0,0188) 
(p-value = 0.0188)
5 mg/kg hver 2. uge. 
5 mg/kg every 2 weeks.
(11,9 vs 14,3 måneder; p = 0,4825) 
(11.9 vs.14.3 months; p = 0.4825)
Resultater for effekt i studie AVF2107g 
Table 4 Efficacy results for trial AVF2107g
Resultaterne fra dette studie er sammenfattet i tabel 16. 
The results of this study are summarised in Table 16.
• kvalme, 
• sickness,
Bevacizumab er, i kombination med paclitaxel, topotecan eller pegyleret liposomal doxorubicin, indiceret til behandling af voksne patienter med platin-resistent recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer, som ikke har gennemgået mere end to kemoterapiregimer, og som ikke tidligere har fået behandling med bevacizumab, andre VEGF-hæmmere eller med VEGFreceptor-målrettede lægemidler (se pkt. 
Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see Section 5.1).
(16,2 vs 12,0 måneder; p = 0,1342) 
(16.2 vs. 12.0 months; p = 0.1342)
Den anbefalede dosis af Avastin administreres som intravenøs infusion og administreres enten som 5 mg/kg eller 10 mg/kg legemsvægt en gang hver 2. uge eller som 7,5 mg/kg eller 15 mg/kg legemsvægt en gang hver 3. uge. 
The recommended dose of Avastin, administered as an intravenous infusion, is either 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks.
LÆGEMIDLETS NAVN Avastin 25 mg/ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT Avastin 25 mg/ml concentrate for solution for infusion.
Det anbefales, at behandlingen fortsættes indtil progression af den underliggende sygdom eller indtil uacceptabel toksicitet (se pkt. 
It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity (see section 5.1).
• Pegyleret liposomal doxorubicin 40 mg/m2 som 1 mg/min i.v.-infusion, kun på dag 1 hver 4. uge. 
• PLD 40 mg/m2 as a 1 mg/min IV infusion on Day 1 only every 4 weeks.
Mindre slimhindeblødninger lokaliseret andre steder, som f.eks. gingival eller vaginal blødning har også været rapporteret som mindre almindelige bivirkninger. 
There have also been less common reactions of minor mucocutaneous haemorrhage in other locations, such as gingival bleeding or vaginal bleeding.
Medianalder var 46,0 år (spændvidde: 20-83) i kemoterapigruppen og 48,0 år (spændvidde: 22-85) i kemoterapi+Avastingruppen. 
The median age was 46.0 years (range: 20−83) in the Chemo alone group and 48.0 years
Patienter med ubehandlede CNS-metastaser, verificeret ved billeddiagnostik eller tegn og symptomer, er rutinemæssigt blevet udeladt af kliniske studier med Avastin. 
Patients with untreated CNS metastases were routinely excluded from clinical trials with Avastin, based on imaging procedures or signs and symptoms.
Hypertensiv encefalopatia 
Hypertensive encephalopathyc
I forhold til kontrolarmen 
Relative to control arm
• infektion eller vævsirritation (inflammation) i øjeæblet, 
• Infection or inflammation of the eye globe,
Det primære endepunkt var progressionsfri overlevelse; de sekundære endepunkter omfattede objektiv responsrate og samlet overlevelse. 
The primary endpoint was progression-free-survival, with secondary endpoints including objective response rate and overall survival.
HR (95% konfidensinterval) p-værdi 
HR (95% CI) p-value
Sammenlignet med 5-FU/FA-kemoterapi alene medførte tillæg af Avastin 5 mg/kg hver 2. uge til 5-FU/FA en højere, objektiv responsrate, længere progressionsfri overlevelse og en tendens til længere overlevelse (se tabel 5). 
The addition of Avastin 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, longer progression-free survival, and a trend in longer survival, compared with 5-FU/FA chemotherapy alone (see Table 5).
Febril neutropeni Leukopeni Neutropenib Trombocytopeni 
Febrile neutropenia, Leucopenia, Neutropeniab, Thrombo-cytopenia
Der er observeret tilfælde af anormaliteter hos fostre, hvor moderen er blevet behandlet med bevacizumab alene eller i kombination med kemoterapeutika med kendt embryotoksicitet (se pkt. 
Cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.6 )
Unormale laboratorieprøver 
Laboratory abnormalities
Inden for hver frekvensgruppe er bivirkningerne anført med de alvorligste først. 
Within each frequency category, adverse reactions are presented in the order of decreasing seriousness.
(17,5 vs 15,0 måneder; p = 0,0584) 
(17.5 vs.15.0 months; p = 0.0584)
Recidiverende ovariecancer 
Rectal haemorrhage
(p-værdi < 0,0001) 
(p-value < 0.0001)
Effektresultater fra studie E3200 
Table 8 Efficacy results for trial E3200
Studiet var et åbent, randomiseret, aktivt kontrolleret, klinisk fase II-studie, som undersøgte Avastin i kombination med 5-FU/FA som 1.-linjebehandling af metastatisk kolorektalkræft. 
This was a phase II randomised, active-controlled, open-labelled clinical trial investigating Avastin in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer.
Studie MO22224 evaluerede bevacizumabs virkning og sikkerhed i kombination med kemoterapi til platinresistent, recidiverende epitelial ovariecancer, tubacancer og primær peritonealcancer. 
Study MO22224 evaluated the efficacy and safety of bevacizumab in combination with chemotherapy for platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Nyrer og urinveje 
Dyspnoea, Rhinitis
Den samlede seponeringsfrekvens på grund af bivirkninger var 8,8 % i kemoterapi-armen og 43,6 % i kemoterapi + bevacizumab-armen (hovedsagelig på grund af bivirkninger af grad 2-3). 
The overall rates of discontinuation due to adverse events were 8.8% in the CT arm and 43.6% in the CT + BV arm (mostly due to Grade 2-3 adverse events) and the median time to discontinuation in the CT + BV arm was 5.2 months compared with 2.4 months in the CT arm.
4.4 og Proteinuri i pkt. 
For further information on proteinuria see section 4.4 and Proteinuria in section 4.8.
Sårhelingskomplikationerb,d 
Wound healing complicationsb,d,
I to efterfølgende studier hos patienter med behandlede hjernemetastaser (som inkluderede omkring 800 patienter) blev der ved sikkerheds-interimanalysen rapporteret om grad 2 
In two subsequent studies in patients with treated brain metastases (which included around 800 patients), one case of Grade 2 CNS haemorrhage was reported in 83 subjects treated with bevacizumab (1.2%) at the time of interim safety analysis (NCI-CTCAE v.3).
Risikoen for at udvikle en rørformet forbindelse (fistel) mellem skeden og et eller andet sted på tarmen kan øges, hvis du har vedvarende livmoderhalskræft, hvis livmoderhalskræften er kommet igen, eller hvis livmoderhalskræften har spredt sig. 
The risk of developing connections between the vagina and any parts of the gut can increase if you have persistent, recurrent or metastatic cervical cancer.
S amlet res pons rate Rate (n) p-værdi 
Rate (n) p-value
I FOLFOX undergruppen var den mediane PFS 8,6 måneder i placebogruppen vs 9,4 måneder for bevacizumab-behandlede patienter, HR = 0,89, 97,5 % konfidensinterval = [0,73-1,08]; p-værdi = 0,1871. 
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026.
Samlet overlevelse - Primær analyse Hazard ratio (95% konfidensinterval) 
Overall survival - Primary analysis1 Hazard Ratio (95% CI)
Avastin vil blive givet sammen med kemoterapibehandling, der indeholder platin. 
Avastin will be administered together with a chemotherapy regimen containing platinum.
Patienter og procentdel af patienter med det bedste objektive respons bekræftet komplet respons eller partielt respons; procent beregnet på grundlag af patienter med målbar sygdom ved baseline 95 % konfidensinterval for one sample binomial ved brug af Pearson-Clopper metoden Ca. 95 % konfidensinterval for forskel mellem to rater ved brug af Hauck-Anderson metoden log-rank-tes t (s tratificeret) 
3 95% CI for one sample binomial using Pearson-Clopper method Approximate 95% CI for difference of two rates using Hauck-Anderson method 5 log-rank test (stratified)
4.4) Brugen af Avastin er blevet forbundet med alvorlige tilfælde af fistler, herunder også letale tilfælde. 
Non-GI Fistulae (see section 4.4) Avastin use has been associated with serious cases of fistulae including reactions resulting in death.
(14,9 vs 11,9 måneder; p = 0,1061) 
(14.9 vs. 11.9 months; p = 0.1061)
Hvis den tåles godt, vil den næste infusion vare 60 minutter. 
If this is well-tolerated the second infusion may be given over 60 minutes.
Leucovorin 200 mg/m2 i.v. 
Leucovorin 200 mg/m2 IV 2 h 5-Fluorouracil
• tilstopning af meget små blodårer i nyrerne, 
• clogging of a very small blood vessel(s) in the kidney,
Der er ikke foretaget studier for at undersøge bevacizumabs farmakokinetik hos patienter med nedsat leverfunktion, idet metabolismen og udskillelsen af bevacizumab i det væsentlige ikke finder sted i leveren. 
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in patients with hepatic impairment since the liver is not a major organ for bevacizumab metabolism or excretion.
Indgivelsesmetode og indgivelsesvej 
Method and route of administration
Effektresultater fra studie BO17704 
Table 13 Efficacy results for trial BO17704
Forskel i responsrate 95 % konfidensinterval for forskel på responsrate4 P (Chi2 test) 
Difference in Response Rates 95% CI for Difference in Response Rates4
(14,9 vs 17,5 måneder; p = 0,4146) 
(14.9 vs. 17.5 months; p = 0.4146)
1Endelig analyse 2Tumorvurdering og responsevaluering var bestemt af investigatorerne udfra GOG RECIST kriterier (revideret RECIST guideline (version 1.1) Eur J Cancer. 
RECIST criteria (Revised RECIST guideline (version 1.1).
• MO22224 evaluerede bevacizumabs virkning og sikkerhed i kombination med paclitaxel, topotecan eller pegyleret liposomal doxorubicin hos patienter med platinresistent, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer. 
• MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Disse blodkar forsyner tumoren med næringsstoffer og ilt. 
The VEGF protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen.
Kemoterapi (n=182) 
CT (n=182)
Den mediane, samlede overlevelse var 20,3 måneder for placebogruppen vs 21,2 måneder for bevacizumab-behandlede patienter i FOLFOX undergruppen, HR = 0,94, 97,5 % konfidensinterval = [0,75-1,16]; p-værdi = 0,4937. 
The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab treated patients in the FOLFOX treatment subgroup, HR=0.94, 97.5% CI = [0.75; 1.16]; p-value = 0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698.
• smerter, inklusive hovedpine, rygsmerter, bækkensmerter og smerter omkring endetarmen, 
• pain, including headache, back pain and pain in the pelvis and anal regions,
Der er ikke foretaget studier for at undersøge bevacizumabs farmakokinetik hos patienter med nedsat nyrefunktion, idet metabolismen og udskillelsen af bevacizumab i det væsentlige ikke finder sted i nyrerne. 
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in renally impaired patients since the kidneys are not a major organ for bevacizumab metabolism or excretion.
Effektresultater for studiet er vist i tabel 14. 
The efficacy results of the study are presented in Table 14.
Nogle af bivirkningerne er almindelige ved behandling med kemoterapi, men Avastin kan forværre disse bivirkninger, når det gives i kombination med kemoterapi, f.eks. palmoplantar erytrodysæstesisyndrom med pegyleret liposomal doxorubicin eller capecitabin, perifer sensorisk neuropati med paclitaxel eller oxaliplatin, negleproblemer og alopeci med paclitaxel og paronykie med erlotinib. 
Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine, peripheral sensory neuropathy with paclitaxel or oxaliplatin, nail disorders or alopecia with paclitaxel, and paronychia with erlotinib.
Avastin kan nedsætte kvinders frugtbarhed. 
Avastin may impair female fertility.
Det primære endepunkt var samlet overlevelse. 
The primary efficacy endpoint was overall survival.
Trombo emboli (venøs)b 
Thromboembolism (venous)
Osteonekrose af kæbenb,c 
Osteonecrosis of the jaw b,c
Kemoterapi + Avastin (n=227) 
Chemotherapy + Avastin (n=227)
I begge behandlingsarme var der ingen bivirkninger som resulterede i dødsfald. 
No AEs leading to death occurred in either treatment arm; all deaths were attributed to disease progression.
Sammenlignet med 5-FU/FA-kemoterapi alene medførte tillæg af Avastin 5 mg/kg hver 2. uge til 5-FU/FV en højere, objektive responsrater, signifikant længere progressionsfri overlevelse og en tendens til længere overlevelse. 
The addition of Avastin 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, significantly longer progression-free survival, and a trend in longer survival as compared to 5-FU/FA chemotherapy alone.
hver 2. uge (eller bevacizumab 15 mg/kg hver 3. uge, hvis det anvendes i kombination med topotecan 1,25 mg/m2 på dag 1-5 hver 3. uge). 
• The chosen chemotherapy was combined with bevacizumab 10 mg/kg IV every 2 weeks (or bevacizumab 15 mg/kg every 3 weeks if used in combination with topotecan 1.25 mg/m2 on Days 1-5 every 3 weeks).
Hvert 4 ml hætteglas indeholder 100 mg bevacizumab svarende til 1,4 mg/ml efter foreskreven fortynding. 
Each 4 ml vial contains 100 mg of bevacizumab, corresponding to 1.4 mg/ml when diluted as recommended.
Ikkemandibulær osteonekrosea,f 
Osteonecrosis of the jawa,b Non-mandibular osteonecrosisa,f
Effektresultater fra studie E4599 
Table 12 Efficacy results for trial E4599
Det primære endepunkt for studiet var progressionsfri overlevelse (PFS) baseret på investigators vurdering. 
The primary endpoint was progression-free survival (PFS) based on independent review assessment.
(17,5 vs 14,3 måneder; p = 0,0609) 
(17.5 vs.14.3 months; p = 0.0609)
• blokering af arterier på grund af en blodprop, 
• blocking of the arteries by a blood clot,
• næseblod, 
• nose bleed,
Objektiv responsrate 
Objective response rate
• Den primære analyse af investigatorvurderet PFS (censureret for CA-125-progressioner og NPT) viser en stratificeret hazard ratio på 0,62 (95 % konfidensinterval: 0,52-0,75, ensidig logrank p-værdi < 0,0001), når CPB15+ sammenlignes med CPP, med en median PFS på 12,0 måneder i CPP-armen og 18,2 måneder i CPB15+-armen. 
• The primary analysis of investigator-assessed PFS (censoring for CA-125 progressions and NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.52-0.75, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 12.0 months in the CPP arm and 18.2 months in the CPB15+ arm.
Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggelederne eller primær bughindekræft, hvor sygdommen er kommet igen mere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil Avastin blive givet sammen med carboplatin og gemcitabin eller sammen med carboplatin og paclitaxel. 
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back at least 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, Avastin will be administered in combination with carboplatin and gemcitabine or with carboplatin and paclitaxel.
Infektion Urinvejsinfektion 
Infection, Urinary tract infection
Randomiserede patienter med stadie III sub-optimalt tumorreduceret sygdom3 
Randomised patients with stage III suboptimally debulked disease3
• Analysen af PFS vurderet af en uafhængig evalueringskomité (censureret for NPT) viser en stratificeret hazard ratio på 0,62 (95 % konfidensinterval: 0,50-0,77, ensidig log-rank p-værdi < 0,0001), når CPB15+ sammenlignes med CPP, med en median PFS på 13,1 måned i CPP-armen og 19,1 måned i CPB15+-armen. 
• The analysis of PFS as determined by the independent review committee (censoring for NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.50-0.77, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 13.1 in the CPP arm and 19.1 months in the CPB15+ arm.
Andre bivirkninger ved behandling med Avastin, der blev set med en højere frekvens hos patienter over 65 år versus patienter ≤ 65 år, var grad 3-4 leukopeni og trombocytopeni (NCI-CTCAE v. 3) samt neutropeni (alle grader), diarré, kvalme, hovedpine og træthed (se pkt. 
Other reactions with a higher frequency seen in patients over 65 were Grade 3-4 leucopenia and thrombocytopenia (NCI-CTCAE v.3); and all Grade neutropenia, diarrhoea, nausea, headache and fatigue as compared to those aged ≤ 65 years when treated with Avastin (see sections 4.4 and 4.8 under Thromboembolism).
Hazard ratio vs placebo-arm (95 % konfidensinterval) 
Hazard ratio vs placebo arm (95% CI) p-value
Tabel 25: Effektresultater fra studie GOG-0240 for Avastinbehandling Kemoterapi (n=225) 
Table 25 Efficacy results from study GOG-0240 by Avastin Treatment
En stor del af patienterne (ca. 63 % IFN/placebo; 55 % Avastin/IFN) fik forskellige ikke-specificerede cancerbehandlinger efter studiets ophør, inklusive antineoplastiske lægemidler, som kan have haft indvirkning på analysen af den samlede overlevelse. 
Avastin/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggeledere eller primær bughindekræft, hvor sygdommen er kommet igen tidligere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil Avastin blive givet sammen med paclitaxel eller topotecan eller pegyleret liposomal doxorubicin. 
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back before 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, Avastin will be administered in combination with paclitaxel, or topotecan, or pegylated liposomal doxorubicin.
• Median PFS-øgning på 2,9 måneder, hazard ratio 0,69 (p = 0,0002, 95 % konfidensinterval 0,56-0,84) 
• Study AVF3694g (capecitabine) • Median PFS increase 2.9 months, HR 0.69 (p = 0.0002, 95% CI 0.56; 0.84)
Patienter med tromboemboliske bivirkninger ≤ grad 3 (NCI-CTCAE v. 3) skal monitoreres nøje. 
need to be closely monitored (NCI-CTCAE v.3).
Resultaterne af dette studie vises i tabel 10. 
The results of this trial are presented in Table 10.
a patienter med målbar sygdom ved baseline Samlet overlevelse Median (måneder) 
a patients with measurable disease at baseline Overall survival
4.4) Der har været sjældne rapporter om symptomer, der stemmer overens med PRES, en sjælden neurologisk forstyrrelse, hos Avastinbehandlede patienter. 
Posterior Reversible Encephalopathy Syndrome (see section 4.4) There have been rare reports of Avastin-treated patients developing signs and symptoms that are consistent with PRES, a rare neurological disorder.
Rektalblødning Stomatitis Obstipation Diarré Kvalme Opkastning Abdominalsmerter 
Rectal haemorrhage, Stomatitis, Constipation, Diarrhoea, Nausea, Vomiting, Abdominal pain
Behandling af platinfølsom recidiverende sygdom: Avastin administreres enten sammen med carboplatin og gemcitabin i 6 og op til 10 behandlingsserier eller sammen med carboplatin og paclitaxel i 6 og op til 8 behandlingsserier, efterfulgt af fortsat behandling med Avastin som monoterapi indtil sygdomsprogression. 
Treatment of platinum-sensitive recurrent disease: Avastin is administered in combination with either carboplatin and gemcitabine for 6 cycles and up to 10 cycles or in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Avastin as single agent until disease progression.The recommended dose of Avastin is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
% patienter med objektivt respons p-value 
% pts with objective response p-value
Antal patienter Samlet overlevelse Median tid (måneder) 95 % konfidensinterval Hazard ratioc p-værdi 
Number of patients Overall survival Median time (months) 95% CI Hazard ratioc p-value
Hazard ratio (95% konfidensinterval) 
Hazard ratio (95% confidence interval)
Det primære endepunkt for studiet var samlet overlevelse, og de sekundære endepunkter var bl.a. progressionsfri overlevelse. 
The primary endpoint was overall survival, with secondary endpoints for the trial including progression-free survival.
Den anbefalede dosis af Avastin, når det anvendes sammen med erlotinib, er 15 mg/kg legemsvægt en gang hver 3. uge som intravenøs infusion. 
The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
• AVF4095g evaluerede bevacizumabs virkning og sikkerhed i kombination med carboplatin og gemcitabin, efterfulgt af bevacizumab som monoterapi, hos patienter med platinfølsom, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer. 
• AVF4095g evaluated the efficacy and safety of bevacizumab in combination with carboplatin and gemcitabine, followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Primær endepunkt 
Primary Endpoint
Arteriel tromboemboli (se pkt. 
Arterial thromboembolism (see section 4.8)
Avastin bruges også hos voksne til behandling af fremskreden kræft i æggestokkene, kræft i æggeledere eller primær bughindekræft. 
Avastin is also used for the treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
c Baseret på et substudie fra NSABP C-08 med 295 patienter. 
Based on a substudy from NSABP C-08 with 295 patients d For additional information refer below within section "Further information on selected serious adverse reactions."